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ORIGINAL RESEARCHExploring the Effects of Vitamin D Supplementation on
ntal Health Status in SubjectsCognitive Functions and MeUnder Methadone Maintenance Treatment
Amir Ghaderi, PhD, Morad Rasouli-Azad, PhD, Mohammad Hassan Farhadi, PhD,
Naghmeh Mirhosseini, PhD, Maryam Motmaen, PhD, Ebrahim Pishyareh, PhD,
Abdollah Omidi, PhD, and Zatollah Asemi, PhDObjectives: Vitamin D deficiency may be linked to several mental
complications including cognitive deficits, depression, and anxiety in
patients under methadone maintenance treatment (MMT). This study
was designed to explore the effect of vitamin D supplementation on
cognitive functions and mental health parameters in subjects under
MMT.
Methods: This randomized, double-blinded, placebo-controlled
clinical trial was carried out among 64 patients under MMT. Par-
ticipants were randomly allocated to receive either 50,000 IU vitamin
D supplements (n¼ 32) or placebo (n¼ 32) every 2 weeks for 24
weeks. Cognitive functions and mental health parameters were taken
at baseline and posttreatment to evaluate relevant variables.
Results: After the 24-week intervention, compared with the placebo,
serum 25(OH) vitamin D levels significantly increased in partic-
ipants who received vitamin D supplements (b 14.50; 95% confi-
dence interval [CI], 13.17–15.83; P< 0.001). In addition, comparedCopyright © 2019 American Society of Addiction Medicine. U
with the placebo, subjects who received vitamin D had a significant
reduction in Iowa Gambling Task (b 6.25; 95% CI, 8.60 to
3.90; P< 0.001), and significant increases in Verbal Fluency Test
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(b 1. 32; 95% CI, 0.27–2.37; P¼ 0.01), Reverse Digit Span (b 2.06;
95% CI, 1.18–2.94; P< 0.001) and visual working memory (b 0.75;
95% CI, 0.33–1.16; P¼ 0.001). Also, vitamin D supplementation
significantly improved BDI (b 2.76; 95% CI, 3.97 to 1.55;
P< 0.001) compared with the placebo. When we applied Bonferroni
correction, LM-Immediate (P¼ 0.07) became nonsignificant, and
other mental health parameters did not alter.
Conclusions: Overall, taking 50,000 IU vitamin D supplements
every 2 weeks for 24 weeks by patients under MMT had beneficial
effects on cognitive functions and some mental health parameters.
Further studies are needed to confirm our findings.
Key Words: cognitive functions, mental health, methadonemaintenance treatment, vitamin D supplementation
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M ethadone maintenance treatment (MMT) is suggestedfor treating opioid use disorder (Kourounis et al.,
2016). In Iran, the prevalence of opioid use is rising and
was nearly 3 times higher than the prevalence worldwide.
About 1.2 million Iranians have opioid dependency with
opium as the most commonly used opioid (82.3%), followed
by opium ashes (as it was boiled down to be prepared for use)
(27.8%), methadone for non-medical usages (16.6%), heroin
and heroin/cracked (crack heroin is the crystal form of heroin)
(16.1%), and morphine (2.6%) (Amin-Esmaeili et al., 2016).
The percentages add up to more than 100% because some
subjects used more than 1 type of opioid. About 500,000
individuals are under methadone and buprenorphine mainte-
nance treatments (Danial et al., 2014). In a study by Darke
et al. (2000), it was reported higher cognitive deficits in a
controlled study (30 subjects and 30 controls). This finding
was replicated by Mazhari et al. (2015). Previous studies have
shown that MMT influences mental health parameters, such as
sleep, anxiety, and depression disturbances (Callaly et al.,
2001; Fan et al., 2014). Earlier, in a cross-sectional study
conducted by Kim et al. (2009), low vitamin D status was
identified among 52% of subjects with MMT. They alsonauthorized reproduction of this article is prohibited.
highlighted that this finding is nonspecific to MMT yet
common among debilitated populations (Kim et al., 2009).
Data representing the circulating vitamin D status in patients
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might be linked to impaired cognitive functions (Llewellyn
et al., 2009), periodontal disease and tooth loss (Dietrich et al.,
2004), and other mental health disorders (Nerhus et al., 2015).
Recently, vitamin D administration was suggested in
patients under MMT (Ghaderi et al., 2017a,b). This may be
because of the beneficial effects of vitamin D intake on
diseases linked to mental health disorders in these patients.
We have previously documented that consuming 50,000 IU
vitamin D every 2 weeks for 12 weeks in individuals under
MMT had favorable effects on mental health parameters
including depression, anxiety, and sleep disorder (Ghaderi
et al., 2017a,b). Current evidence has reported the controver-
sial effects of vitamin D supplementation on mental health
parameters and cognitive functions in patients not undergoing
MMT. We have previously demonstrated that vitamin D
administration at a dosage of 50,000 IU/week for 8 weeks
to patients with major depressive disorder had beneficial
effects on the Beck Depression Inventory (BDI) (Sepehrma-
nesh et al., 2016). However, a meta-analysis study by Gowda
et al. (2015) did not show any significant reduction in
depression score following vitamin D supplementation. More-
over, 2 other meta-analyses (Li et al., 2014; Shaffer et al.,
2014) of randomized controlled trials, evaluating the efficacy
of vitamin D supplementation on depression in adults, did not
reveal any significant effect on depressive symptoms. Also,
joint supplementation with vitamin D3 (400 IU) and calcium
(1000 mg) did not affect the treatment of cognitive
impairment in elderly women (Rossom et al., 2012). More-
over, vitamin D supplementation (50,000 IU/week) for
52 weeks to persons undergoing dialysis did not reduce
depressive symptoms (Wang et al., 2016). Excess amount
of vitamin D might cause hypercalcemia, which is a strong
indication of vitamin D toxicity along with an increase in
urination and thirst (Koul et al., 2011). Left untreated, hyper-
calcemia might result in extra deposits of calcium in soft
tissues and organs. such as the kidneys, liver, and heart,
resulting in pain and organ damage (Koul et al., 2011).
Vitamin D may improve mental health status through
regulating the synthesis of serotonin (5- hydroxyltryptamine)
in brain (Stockmeier, 2003). In addition, vitamin D might
improve parameters of mental health through increasing the
expression of neurotrophic factors, the stimulation of adult
neurogenesis, and the regulation of calcium homeostasis
(Garcion et al., 2002; Bourre, 2006; McCann and Ames,
2008). McCann and Ames (2008) concluded that the current
experiential evidence does not yet fully satisfy causal criteria
for cognitive functions. They nevertheless supported supple-
mentation as ‘‘prudent’’ among debilitated populations
(McCann and Ames, 2008). Numerus studies demonstrated
that MMT is linked to impaired cognitive functions and this
impairment included a range of mental function domains,
such as phonemic word fluency, psychomotor performance,
speed of processing, such as Trial Making Test (TMT),
attention, long-term and short-term memory scales, such as
Digit Span (DGSP), and decision-making process, such as
Ghaderi et al.Copyright © 2019 American Society of Addiction Medicine. Un
Iowa Gambling Task (IGT) (Darke et al., 2000; Specka et al.,
2000, Mintzer and Stitzer, 2002; Mazhari et al., 2015). On the
other hand, previous studies have documented that vitamin D
2
may influence brain and neuron development as well as have
beneficial effects on cognitive functions, such as speed of
processing, memory function, and decision-making in
patients without MMT (Soni et al., 2012; Annweiler et al.,
2013). To our best knowledge, data on the effects of vitamin D
supplementation on cognitive function improvement in
patients under MMT are limited. Therefore, we assumed that
the combination therapy of vitamin D and methadone in
opioid withdrawal protocols could be introduced for increas-
ing the quality of life and decreasing the MMT-related side
effects. The aim of the current study was to investigate the
effects of vitamin D supplementation on cognitive functions
and mental health status in subjects under MMT.
METHODS
Trial Design and Participants
This randomized, double-blinded, placebo-controlled
clinical trial was registered in the Iranian website for regis-
tration of clinical trials at http://www.irct.ir:
IRCT2017101133079N4, the Primary Registry in the WHO
Registry Network set up in collaboration with Ministry of
Health and Medical Education. This study was conducted
among 64 men under MMT, ages 18 to 60 years who were
referred to the Golabchi Clinic in Kashan, Iran, from October
2017 to March 2018. Study protocol was approved by the
research ethics committee of Kashan University of Medical
Sciences (KAUMS). This investigation was conducted in
accordance with the Declaration of Helsinki and informed
consent was signed by all participants. All informed consent
forms were reviewed by the research ethics committee of
KAUMS. Exclusion criteria were not living in Kashan, taking
vitamin D, multivitamin-mineral, and antioxidant supple-
ments during the last 3 months before the intervention.
Study Design
At the onset of the study, to avoid potential confounding
effects, all participants were stratified randomized according
to age and BMI. Then, participants in each block were
randomly allocated into 2 treatment groups to take either
50,000 IU vitamin D (Zahravi, Tabriz, Iran) or placebo
(Zahravi, Tabriz, Iran) (n¼ 32 each group) every 2 weeks
for 24 weeks. The placebos were matched in terms of their
colour, shape, size, packaging, smell, and taste with the
vitamin D3 capsules. We used the above-mentioned dose
of vitamin D based on a prior study published in subjects
with chronic liver diseases (Stokes et al., 2016). Methadone
was consumed in the form of syrup by patients. To evaluate
the compliance rate, participants’ serum 25(OH) vitamin D
levels were measured at weeks 0, 8, 16, and 24 of the
intervention using an enzyme-linked immunosorbent assay
(ELISA) method. All patients completed a 3-day food record
and 3 physical activity records as metabolic equivalents
(METs) (Ainsworth et al., 2000) at weeks 0, 6, 12, 18, and
24 of the intervention. To calculate participants’ nutrient
intakes using 3-day food records (Sciences, 2002), we applied
J Addict Med  Volume 00, Number 00, Month/Month 2019authorized reproduction of this article is prohibited.
Nutritionist IV software (First Databank, San Bruno, CA)
modified for Iranian food pattern. Previous studies have
reported the impact of dietary intakes and physical activity
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itamon cognitive functions and mood state (Ortega et al., 1997;
Ruscheweyh et al., 2011; Loprinzi and Kane, 2015), therefore,
we used food record and physical activity questionnaire in
order to incorporate dietary intakes and physical activity as
the confounders in this study.
Anthropometric Measures
Patients’ anthropometric measurements were con-
ducted using a standard scale (Seca, Hamburg, Germany)
at baseline and 24 weeks after supplementation. Body Mass
Index (BMI) was calculated as weight in kilograms divided
by height in square meters . Previous studies exploring
the relationship between indices of central adiposity and
cognitive functions are based on being older adults (65þ)
(Driscoll et al., 2011), cross-sectional studies (Nourhashemi
et al., 2002), or using small sample sizes (Yoon et al., 2012).
Therefore, we recorded participants’ anthropometric mea-
sures to be used as the confounder in this study.
Outcomes
Cognitive functions, including TMT, IGT, Wechsler
Memory Scale (WMS), Scored General Intelligence Test
(SGIT), and DGSP backwards in Wechsler intelligence Scale
were considered as the outcomes of interest and BDI and Beck
Anxiety Inventory (BAI) were considered as the secondary
outcomes.
Clinical Assessment
TMT is normally administered using 2 sub-components,
which are known as TMT-A and TMT-B (Stuss et al., 2001).
TMT measures a variety of cognitive functions including
attention, visual search and scanning, sequencing and shifting,
psychomotor speed, abstraction, and cognitive flexibility
(Salthouse, 2011). TMT is normally administered using 2
sub-components, which are known as TMT-A and TMT-B. In
TMT-A, the patient is presented with encircled numbers from
1 to 25 randomly distributed on a sheet of paper, and they are
instructed to link the numbers in ascending order (ie, 1-2-3. . .)
using a pen or pencil. In TMT-B, a second sheet includes both
encircled numbers and letters that the patient must link in
alternating ascending order (ie, 1-A-2-B-. . .). Task perfor-
mance in each part is typically quantified by measuring the
completion time, with TMT-B taking longer to complete. IGT
is a useful tool for analyzing the individuals’ decision-making
process. The participants were faced with 4 cards (Businelle
et al., 2008; Turnbull et al., 2014). Memory scale was
measured by Logical Memory (I and II). It is a subtest of
Wechsler Memory Scale (WMS), assessing the narrative
memory under a free recall condition (Wechsler, 1997).
Scored General Intelligence Test (SGIT) is one of the few
tests that attempts to measure general intelligence and can be
administered by the clinician during the psychiatric interview
(Canivez et al., 2017). Short-term auditory memory was
measured by DGSP backwards in Wechsler Memory Scale-
III (WMS- III) (Wechsler, 1997). The examiner read a list of 3
to 9 digits calmly and loudly, and the participant should read
J Addict Med  Volume 00, Number 00, Month/Month 2019 VCopyright © 2019 American Society of Addiction Medicine. U
them in the same way after listening to each list. DGSP is
normally administered as 2 sub-components known as DGSP-
Straight and DGSP-Reverse (Jasinski et al., 2011). The FAS
 2019 American Society of Addiction MedicineTest, a subtest of the Neurosensory Center Comprehensive
Examination for Aphasia (Crockett, 1977) is a measure of
phonemic word fluency. BDI was assessed using a self-
compiled questionnaire (Beck et al., 1961). BDI was assessed
using a self-compiled questionnaire (Beck et al., 1961). The
internal stability of the test among Iranian students (Persian
version of BDI-II) was moderate-to-good (Cronbach a ¼
0.58) and its reliability by test-retest was 0.73 (Meygoni
and Ahadi, 2012). Anxiety was measured using BAI-21,
which was developed by Beck et al. (1988) to determine
the frequency of anxiety symptoms in adults. Kaviani and
Mousavi (2008) approved the validity and reliability of Per-
sian version of BAI among Iranian normal population as well
as clinically anxious patients.
Biochemical Assessment
At baseline and week 24 of the treatment, 10 mL fasting
blood samples were collected from each patient at Kashan
reference laboratory. Serum 25-hydroxyvitamin D values
were measured using a commercial ELISA kit (IDS, Boldon,
UK) with intra- and inter-assay coefficient variances (CVs) of
lower than 7%.
Sample Size
Sample size was calculated using the formula suggested
for randomized clinical trials. Type 1 (a) and type 2 errors (b)
were defined as 0.05, and 0.20 to have the study power of
80%. We did not find a similar study regarding the effects of
vitamin D on primary outcomes of this study for determining
sample size; therefore, the sample size was calculated based
on the effects of vitamin D supplementation on BDI. On the
basis of a previous published study (Sepehrmanesh et al.,
2016), we used 6.6 as the effect size (the mean difference) of
the BDI and 8.9 as SD. So, 30 participants were required in
each treatment group. Considering 20% dropouts in each
group, the final sample size was 35 participants in each
intervention group.
We used the standard deviation of the BDI from the
Sepehrmanesh et al. (2016) article (8.9) with similar study
design to ours. For sample size calculation, the minimal
clinically important effect size is also required, which is
determined by the researcher (it should not be derived from
the literature). In addition, we hypothesized that the effect size
of 6.6 for BDI would result in a significant change in BDI of
patients under MMT. Also the standardized effect size equals
6.6/8.9¼ 0.74, which is considered as a large effect size
according to Cohen (Mansournia and Altman 2018). Using
SD of 8.9, we have at least 80% power (probability) of
detecting a difference of equal to or greater than 6.6 (if it
really exists) as statistically significant at the 5% level.
Randomization
Randomization was conducted using computer-gener-
ated random numbers. Randomization and allocation were
concealed from the researchers and patients until the comple-
tion of final analyses. The randomized allocation sequence,
in D Supplementation and Methadone Maintenance Treatmentnauthorized reproduction of this article is prohibited.
enrolling patients and allocating them into intervention
groups were performed by a trained staff at the clinic. Another
staff, who was not involved in the trial and not aware of
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bottles of capsules.
Statistical Analysis
To test the normality of variables, Kolmogorov-Smir-
nov test was used. Anthropometric and dietary characteristics
of the intervention groups were compared using independent
sample t-test. Multiple linear regression models were used to
assess treatment effects on study outcomes after adjusting for
confounding variables including the baseline values of out-
comes as well as age and BMI at baseline. The effect sizes
were presented as the mean differences with 95% confidence
Ghaderi et al.Copyright © 2019 American Society of Addiction Medicine. Un
intervals (CIs). Bootstrapping was also used as a sensitivity
analysis of CIs and inverse probability weighting was used to
account for loss-to-follow-up, but the results did not change
Randomized (n
Allocated to placebo (n=35)
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(n=425)
FIGURE 1. Summary of patient flow.
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substantially. Bonferroni correction (ie, multiplying P-values
by the number of tests) was applied to account for multiple
outcome testing. The P-values of <0.05/7 or 0.007 were
considered statistically significant. All statistical analyses
used the Statistical Package for Social Science version 18
(SPSS Inc., Chicago, IL).
RESULTS
Three individuals in the treatment group [(because of
moving to other city (n¼ 1) and not interested to be part of
research anymore (n¼ 2)] and 3 in the placebo group [(because
of moving to other city (n¼ 2) and not interested in research
J Addict Med  Volume 00, Number 00, Month/Month 2019authorized reproduction of this article is prohibited.
(n¼ 1)] withdrew from the trial because of personal reasons.
Finally, 64 participants [vitamin D (n¼ 32) and placebo
(n¼ 32)] completed the study (Fig. 1). The compliance rate
=70)
Allocated to intervention (n=35)






- Not meeting inclusion criteria (n=10)
- Not living in Kashan (n=10)
 the clinic 
Excluded (n=335) 
- Loss of interest for participation in the 
research (n=335)
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TABLE 1. General Characteristics of the Study Participants
Placebo Group (n¼ 32) Vitamin D Group (n¼ 32)
Age, y 40.8 9.5 37.5 10.8
Height, cm 170 6.6 169.0 9.1
Weight at study baseline, kg 74.8 11.6 71.2 12.3
Weight at the end-of-trial, kg 75 10.8 71.3 11.5
Weight change, kg 0.15 1.5 0.03 1.6
BMI at study baseline, kg/m2 25.84 3.5 24.94 4.0
BMI at the end-of-trial, kg/m2 25.91 3.3 24.96 3.7
BMI change, kg/m2 0.07 0.58 0.02 0.55
SGIT 33.5 3.1 32.9 3.4
J Addict Med  Volume 00, Number 00, Month/Month 2019 Vitamin D Supplementation and Methadone Maintenance Treatmentin our study was high; more than 90% of capsules were taken
during the trial in both intervention groups. To determine the
compliance rate, the remaining capsules were counted and
subtracted from the total amount of supplements provided to
the participants. There were no adverse reactions reported by
participants following the consumption of vitamin D in patients
with MMT.
Mean age and anthropometric measures including
height, weight, SGIT (IQ) and BMI at both baseline and
end-of-trial were not significantly different between vitamin
D and placebo groups (Table 1).
Macro- and micronutrient intakes, calculated using a
3-day food record, were not significantly different between 2
Data are meanSDs.
SGIT, Scored General Intelligence Test.Copyright © 2019 American Society of Addiction Medicine. U
treatment groups (data not shown).
After the 24-week intervention, compared with the
placebo group, serum 25(OH) vitamin D levels significantly






Baseline Week 24 Baseline
25-OH-vitamin D (ng/mL) 13.1 3.6 12.0 4.1 14.1 4.2
IGT 28.2 4.5 29.2 3.5 29.3 3.6
TMT subscales
TMT-A 21.0 2.6 20.7 2.9 20.9 2.4
TMT-B 54.3 7 51.8 4.9 52.7 7.7
Verbal Fluency Test (FAS test)
Numbers of total words 35.3 2.6 35.4 3.3 36.7 3.2
LM subscales
LM-Immediate 28.2 3.5 30.38 2.4 28.9 3.8
LM-Delayed 9.5 1.5 10.6 1.1 10.1 1.4
DGSP
DGSP-Straight 9.1 1.9 10.6 1.7 9.0 2
DGSP-Reverse 8.7 1.6 7.4 1.7 8.8 1.4
Visual working memory 3.53 0.91 4.02 0.52 3.99 0.9
BAI 15.1 2.7 17.8 5.2 16.7 4.8
BDI 15.9 4.4 16.1 2.9 14.8 5.6
Data are meanSDs.
‘‘Outcome measures’’ refers to the change in values of measures of interest between basel
(Vitamin D group¼ 1 and placebo group¼ 0)].
yObtained from multiple regression model (adjusted for baseline values of each bioche
zObtained from multiple regression model and corrected using Bonferroni correction (P
BAI, Beck Anxiety Inventory; BDI, Beck Depression Inventory; CI, confidence interval;
Span; IGT, Iowa Gambling Task; LM, Logic Memory; LM-Delayed, Delayed Logic Memo
Making Test-form A; TMT-B, Trial Making Test-form B.
 2019 American Society of Addiction Medicineincreased in patients receiving vitamin D supplements
(b 14.50; 95% CI, 13.17, 15.83; P< 0.001) (Table 2). In
addition, compared with the placebo, subjects who received
vitamin D had a significant reduction in IGT (b6.25; 95% CI,
8.60 to3.90; P< 0.001), and significant increases in Verbal
Fluency Test (b 2.82; 95% CI, 0.78–4.86; P¼ 0.007), LM-
Immediate (b 1. 32; 95% CI, 0.27–2.37; P¼ 0.01), DGSP-
Reverse (b 2.06; 95% CI, 1.18–2.94; P< 0.001) and visual
working memory (b 0.75; 95% CI, 0.33–1.16; P¼ 0.001).
Also, vitamin D supplementation significantly improved BDI
(b2.76; 95% CI,3.97 to1.55; P< 0.001) compared with
the placebo. There was no significant effect of vitamin D
administration on measured cognitive functions and mentalnauthorized reproduction of this article is prohibited.
health parameters. When we applied Bonferroni correction,
LM-Immediate (P¼ 0.07) became nonsignificant, and other
mental health parameters did not alter.
tive Functions and Mental Health Parameters in Methadone
in D Group
(n¼ 32)
Difference in Outcome Measures
Between Vitamin D and Placebo
Treatment Groups
Week 24 b (95% CI) Py Pz
27.5 4.2 14.50 (13.17,15.83) <0.001 <0.001
23.1 3.1 6.25 (8.60, 3.90) <0.001 <0.001
20.7 1.7 0.11 (1.38, 1.16) 0.86 >0.99
50.5 4.8 0.91 (3.52, 1.70) 0.48 >0.99
38.6 4.2 2.82 (0.78, 4.86) 0.007 0.04
32.2 2.1 1.32 (0.27, 2.37) 0.01 0.07
10.9 1.2 1.49 (0.33, 2.66) 0.33 >0.99
10.1 1.5 0.56 (1.39, 0.26) 0.17 >0.99
9.3 1.6 2.06 (1.18, 2.94) <0.001 <0.001
4 4.88 1.05 0.75 (0.33, 1.16) 0.001 0.007
19.0 3.7 1.29 (1.02, 3.61) 0.26 >0.99
12.7 4.6 2.76 (3.97, 1.55) <0.001 <0.001
ine and week 24. b [difference in the mean outcomes measures between treatment groups




DGSP, Digit Span; DGSP-Reverse, Reverse Digit Span; DGSP-Straight, Straight Digit
ry; LM-immediate, Immediate Logic Memory; TMT, Trial Making Test; TMT-A, Trial
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We evaluated the effects of vitamin D supplementation
on mental health status and cognitive functions after 24 weeks
in subjects under MMT. Our study evidenced that taking
vitamin D supplements for 24 weeks by subjects under
MMT, compared with the placebo, improved BDI, IGT,
FAS, LM-Immediate, DGSP-Reverse, and visual working
memory, but did not affect BAI, TMT subscales, LM-Delayed
and DGSP-Straight. When we applied Bonferroni correction
for multiple outcome testing, LM-Immediate became nonsig-
nificant, and other mental health parameters did not alter.
Previous studies have reported that hypovitaminosis D and
low BMD were present in a majority of subjects recruited
from an MMT program (Kim et al., 2006, 2009). On the basis
of these findings, vitamin D may be an appropriate adjunct
therapy for opioid-dependent patients under treatment with
MMT. It must be kept in mind that in the vitamin D group,
increased levels of serum 25(OH) vitamin D were statistically
significant, yet not clinically significant. Long-term interven-
tions and higher dosage of vitamin D might be required to
provide greater changes in serum 25(OH) vitamin D levels.
Effects on Mental Health
We found that vitamin D administration to patients
under MMT for 24 weeks improved depression indexes,
but did not affect anxiety scores. Several studies have inves-
tigated the effects of vitamin D supplementation on mental
health parameters in participants with and without MMT, but
the results are controversial. Ghaderi et al. (2017) observed
that vitamin D supplementation (50,000 IU/week) for
12 weeks improved Pittsburgh Sleep Quality Index and
BDI in patients under MMT. Huang et al. (2013) also found
that vitamin D supplementation at a dosage of 50,000 IU/week
improved various aspects of quality of life in veterans with
multiple areas of chronic pain. We specified 2 trials demon-
strating a significant effect of vitamin D intake on depression
and anxiety symptoms (Lansdowne and Provost, 1998; Jorde
et al., 2008), although no considerable effect was observed by
others (Vieth et al., 2004; Sanders et al., 2011). In another
study, vitamin D supplementation (40,000 IU/week) for
6 months had no significant effect on depression scores
(Kjaergaard et al., 2012). The accurate mechanism of vitamin
D in the brain and its effects on mental health parameters is
not completely understood. Increased expression of tyrosine
hydroxylase gene and promoted dopamine, noradrenalin, and
adrenalin bioavailability might clarify the beneficial effects of
vitamin D on mental health parameters (Humble, 2010;
Khoraminya et al., 2013).
Effects on Cognitive Functions
Our study demonstrated that consuming vitamin D
supplements for 24 weeks by patients under MMT signifi-
cantly improved IGT, FAS, LM-Immediate, DGSP-Reverse,
and visual working memory, but did not affect TMT sub-
scales, LM-Delayed and DGSP-Straight. When we applied
Bonferroni correction for multiple outcome testing, LM-
Ghaderi et al.Copyright © 2019 American Society of Addiction Medicine. Un
Immediate became nonsignificant, and other mental health
parameters did not alter. Although data presenting the effects
of vitamin D supplementation on cognitive functions in MMT
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subjects are scarce, several studies have evaluated the effects
of vitamin D supplementation on cognitive functions in
participants not taking MMT. In a meta-analysis by Annweiler
et al. (2013), higher vitamin D concentrations were correlated
with better working memory performance. Also, Assmann
et al. (2015) found that higher 25(OH) D concentrations were
linked to a better working memory. Furthermore, receiving
vitamin D (200 IU/day) was linked to lower mean cognitive
functions scores (Annweiler et al., 2010b). However, no
evidence showed the association between vitamin D levels
and cognitive disturbance among elder women (Annweiler
et al., 2010a). In a meta-analysis by Bolland et al. (2010),
vitamin D intakes were linked to a 30% increased risk of
myocardial infarction, stroke, and with small yet nonsignifi-
cant increases in cognitive impairment. Moreover, Dean et al.
(2011) observed that vitamin D supplementation at a dosage
of 5000 IU/week for 6 months did not influence cognitive or
emotional functioning in healthy young adults. In the current
study, we did not find any significant effect of vitamin D
supplementation on TMT-A, TMT-B, LM-Delayed, DGSP-
Straight, and BAI. The controversial findings might be
explained through different study designs, baseline values
of measured cognitive functions and mental health parame-
ters, baseline levels of 25-OH-vitamin D, different dosages
and type of vitamin D used, and the duration of supplemen-
tation as well as different participants’ characteristics. In order
to improve some of the cognitive functions and mental health
parameters like TMT-A, TMT-B, LM-Delayed, DGSP-
Straight, and BAI, individuals might need higher concentra-
tions of 25-OH-vitamin D. Other parameters including par-
ticipants’ characteristics like cognitive functions and mental
health parameters, higher doses of vitamin D or longer
intervention might be required to provide appropriate circu-
lating levels of 25-OH-vitamin D necessary for improving
TMT-A, TMT-B, LM-Delayed, DGSP-Straight, and BAI.
Therefore, further studies were required to confirm our
findings. The impact of vitamin D on IGT, FAS, LM-
Immediate, DGSP-Reverse, and visual working memory also
might be related to the excitatory effects of vitamin D on
acetylcholine release (Izquierdo, 1990). Acetylcholine is an
important neurotransmitter for learning and memory consoli-
dation, and elevated levels of acetylcholine result in improved
memory.
There were some limitations in this study. In the current
study, we did not specify vitamin D intake through sun
exposure. This should be considered in the interpretation of
our findings as one of the limitation of this study. In addition,
we did not evaluate biomarkers of inflammation and oxidative
stress in the current study. In the current study, cognitive
functions, including TMT, IGT, WMS, SGIT, and DGSP were
considered as the primary outcomes. We did not find a similar
study regarding the effects of vitamin D on primary outcomes
of this study for determining sample size; therefore, the
sample size was calculated based on one of the secondary
outcomes (BDI). As the study is not powered to detect
differences in primary outcome measures, one cannot make
J Addict Med  Volume 00, Number 00, Month/Month 2019authorized reproduction of this article is prohibited.
any definite conclusion about them. Therefore, further large-
scale studies are required to examine the effect of vitamin D
supplementation on cognitive functions and mental health
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calculation based on the primary outcomes.
CONCLUSIONS
Overall, we found that taking vitamin D supplements
for 24 weeks by subjects under MMT improved BDI, IGT,
FAS, LM-Immediate, DGSP-Reverse, and visual working
memory, compared with the placebo, yet did not affect
BAI, TMT subscales, LM-Delayed, and DGSP-Straight. Fur-
ther studies are needed to show the relative impact of vitamin
D supplementation on a debilitated population versus MMT
and perhaps larger samples should be used to study the
parameters of vitamin D supplementation as a public health
measure. Furthermore, additional studies are required to look
at the functional improvement in patients under MMT fol-
lowing vitamin D supplementation and other micronutrients.
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